IRONWOOD PHARMACEUTICALS INC (IRWD)
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Ironwood Pharmaceuticals, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | 4.50 | 4.55 | 4.35 | 4.38 | 187,042 |
| Nov 6, 2026 | 4.26 | 4.44 | 4.10 | 4.39 | 3,963,433 |
| Nov 5, 2026 | 4.30 | 4.41 | 3.84 | 4.03 | 4,989,224 |
| Nov 4, 2026 | 3.61 | 3.80 | 3.58 | 3.77 | 2,571,635 |
| Nov 3, 2026 | 3.51 | 3.57 | 3.40 | 3.50 | 1,947,081 |
| Nov 2, 2026 | 3.50 | 3.58 | 3.43 | 3.46 | 1,299,775 |
| Oct 30, 2026 | 3.59 | 3.64 | 3.45 | 3.50 | 1,470,622 |
| Oct 29, 2026 | 3.65 | 3.69 | 3.58 | 3.62 | 1,367,777 |
| Oct 28, 2026 | 3.46 | 3.63 | 3.46 | 3.61 | 1,411,435 |
| Oct 27, 2026 | 3.52 | 3.54 | 3.45 | 3.51 | 1,655,777 |
| Oct 26, 2026 | 3.49 | 3.54 | 3.45 | 3.50 | 1,131,286 |
| Oct 23, 2026 | 3.52 | 3.54 | 3.38 | 3.46 | 1,261,259 |
| Oct 22, 2026 | 3.50 | 3.60 | 3.49 | 3.57 | 1,041,159 |
| Oct 21, 2026 | 3.68 | 3.69 | 3.52 | 3.55 | 1,519,126 |
| Oct 20, 2026 | 3.57 | 3.71 | 3.52 | 3.63 | 1,641,394 |
| Oct 19, 2026 | 3.53 | 3.59 | 3.48 | 3.56 | 1,679,094 |
| Oct 16, 2026 | 3.73 | 3.73 | 3.48 | 3.50 | 2,531,353 |
| Oct 15, 2026 | 3.63 | 3.87 | 3.63 | 3.77 | 2,044,808 |
| Oct 14, 2026 | 3.55 | 3.63 | 3.51 | 3.60 | 1,223,260 |
| Oct 13, 2026 | 3.74 | 3.78 | 3.54 | 3.59 | 2,106,376 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 DENNER ALEXANDER J | Director | Grant/Award | 3.7K | -- | Sep 15, 2026 |
 Silber Jeffrey | SVP, CMO, Head-Res&Drug | Grant/Award | 137.0K | -- | Jul 20, 2026 |
 Silver Ronald | PFO & PAO | Sale | 127.9K | $578.1K | Jul 7, 2026 |
 McHugh Julie | Director | Grant/Award | 63.5K | -- | Jun 16, 2026 |
| McHugh Julie | Director | Sale | 21.6K | $80.5K | Jun 16, 2026 |
 Moukheibir Catherine | Director | Grant/Award | 63.5K | -- | Jun 16, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 17.8M | 10.7% | 13F |
Armistice Capital, LLC · also on 13F· joint filing· may incl. warrants· filed May 2026 | 15.0M | 9.1% | 13G |
ARMISTICE CAPITAL, LLC | 13.9M | 8.4% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jul 2026 | 13.4M | 8.1% | 13G |
Sarissa Capital Management LP | 9.2M | 5.6% | 13F |
STATE STREET CORP | 8.8M | 5.3% | 13F |
BANK OF AMERICA CORP /DE/ | 8.7M | 5.2% | 13F |
Renaissance Technologies LLC · also on 13F· joint filing· may incl. warrants· filed May 2026 | 8.1M | 4.9% | 13G |
RENAISSANCE TECHNOLOGIES LLC | 8.0M | 4.8% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 6.6M | 4.0% | 13F |
Insiders
- DENNER ALEXANDER JDirector
- Silber JeffreySVP, CMO, Head-Res&Drug
- Silver RonaldPFO & PAO
- McHugh JulieDirector
- Moukheibir CatherineDirector
- Kessler Marla LDirector
- Currie Mark GDirector
- Duane Jon RDirector
- Shepard JayDirector
- MCCOURT Thomas AChief Executive Officer
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions.
Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis.
Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
based on 165.55M shares outstanding
US30d Avg
1.89M
60d Avg
2.07M
90d Avg
1.93M